YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

News & Reports

March 10, 2010 | Thermo Debuts LIMS-on-Demand
Thermo Fisher Scientific launched LIMS-on-Demand, which the company says can significantly reduce the cost of owning and managing a LIMS. This is Thermo’s first software-as-a-service (SaaS) LIMS offering which the company characterizes as an enterprise-class LIMS. Thermo created a web-presence with a variety of collateral to explain the new offering, which is hosted by OpSource, leading providers of On-Demand solutions.

“LIMS-on-Demand delivers the benefits of an on-premise LIMS at a lower cost and with very little implementation time," said Dave Champagne, VP and GM of Thermo Fisher Scientific's Informatics business. "With built-in workflows, the ability to capture, store and analyze lab data, monitor resources and integrate with instrumentation, we are enabling more laboratories around the world to experience the competitive advantages of LIMS." For more information visit

This is from Thermo’s FAQ Sheet:

“What is Thermo Scientific LIMS-on-Demand?
On-Demand software is gaining momentum in a variety of applications and industries. It is delivered by an application service provider (ASP) which users access via a web browser. The ASP is responsible for all aspects of the software including maintenance, upgrades, and security. Additional fees may be associated with any implementation, training, and configuration services the user requires.

“Thermo Scientific LIMS-on-Demand is a recurring subscription based model hosted from our secure datacenter and delivered via a web browser.  With LIMS-on-Demand, lab personnel can focus on their core competencies without the additional responsibility of maintaining lab software and databases. Web access enables rapid deployment because site installation is not required. Anytime, anywhere system access delivers identical applications and data to workers regardless of location.”

Waters Offers New Agilent Services
Waters announced today a suite of new services for Agilent liquid and gas chromatographs controlled by Waters Empower Chromatography Software. The new maintenance, repair, and compliance services are being offered in response to demand from laboratories for single-point-of-contact and ownership of support services for both Waters and Agilent systems, according to the company.

“Cost relief for today’s laboratories requires the adoption of innovative technologies that have a meaningful impact,” said Bruce Ryan, Waters Director, Service Marketing, in a release. Managing chromatography data in a busy analytical laboratory is an ever-increasing challenge. The task is compounded when labs use a mix of liquid chromatographs and gas chromatographs from different suppliers. To simplify data management in a multi-vendor environment, laboratories often choose a single chromatography data system capable of operating chromatographs from a variety of manufacturers. For more information.

Genedata Adds Statistical Tool
The company launched Genedata Analyst, an integrated statistical and data analysis platform with advanced visualization capabilities. Built on client-server architecture, Genedata Analyst handles huge and complex data sets of billion-plus data points while supporting small research groups or hundreds of users.

Simultaneously managing data from different sources, Genedata Analyst gives researchers and biostatisticians a secure and scalable data-mining platform, which can be tightly integrated with existing research IT ecosystems. New to the Genedata solutions portfolio, Genedata Analyst will be demonstrated at the Society of Toxicology 49th Annual Meeting's ToxExpo (March 8 -10; Booth #1837). More Information.

MicroConstants Offer Nanosizing Technology
MicroConstants, a CRO specializing in bioanalytical and pharmacokinetic analysis, acquired access to a new nanosizing technology that transforms water insoluble compounds into nanoparticles, making formulation preparation and dosing for toxicology studies easier. Many commercially available medications and a large majority of New Chemical Entities (NCEs) produced are poorly soluble.

Nanoparticles provide a much larger surface area thereby increasing the dissolution rate resulting in enhanced absorption. Nanosizing compound can promote improved drug loading, exposure and bioavailability, and faster onset (earlier Tmax), according to the company. More information.

Ocimum Biosolutions Adds Board Member
David U’Prichard, President at Druid Consulting LLC, has joined the company’s Board of Directors effective immediately. Dr. U’Prichard holds board positions in several life sciences companies globally that include Life Technologies, Inc., Oxagen, Cyclacel and Silence Therapeutics plc. Dr. David U’Prichard is also a venture partner at Red Abbey Venture Partners.

Entelos, RegeneMed Release iToxFx
Biosimulation specialist Entelos and RegeneMed, a tissue-based drug discovery and regenerative medicine company, announced released iToxFX service to help pharmaceutical companies rapidly screen novel compounds for potential toxicity issues. iToxFX can rapidly analyze the toxicogenomic profile of drug-treated rat hepatocytes (liver cells) and generate analytical reports within minutes.

"In traditional toxicology, adverse events and potential side effects are often discovered relatively late in drug development, making it a costly endeavor" said Alan Roter, Vice President of Informatics at Entelos. "For companies with little toxicogenomics expertise or small research budgets, iToxFX provides a quick analysis of a new drug’s potential safety profile, identifying likely mechanisms of toxicity much earlier in the development process.”

iToxFX leverages Entelos' DrugMatrix reference database comprised of Entelos-generated data from over 18,000 vehicle and drug-treated animal tissue samples and cultures, based on 600 marketed drugs and toxicology standards. Read release.

Symyx Transitions to Pure-Play Scientific Software
Symyx announced its successful transition to a pure-play scientific software company with the completion of the planned divestiture of its High Productivity Research (HPR) business unit assets, previously announced on February 11, 2010.  The divested assets will be owned and operated by FreeSlate, Inc. (formerly HPR Global, Inc.) in HPR's current location in Sunnyvale, California.

"This divestiture allows Symyx to operate as a focused, positive cash-flow software business, and to capitalize on its growth opportunities," said Isy Goldwasser, Symyx's chief executive officer. "As a pure-play scientific software company, we can better drive towards our core goals for 2010 of achieving the clear #1 position in the fast-growing electronic lab notebook market, of scaling our business and core franchises, and delivering consistent improvement in profitability, helping us track to our 20% adjusted EBITDA target for 2011."

"FreeSlate builds upon a tradition of enabling scientific R&D organizations to accelerate the pace of discovery while reducing costly, complex procedures that hinder efficiency," said John Senaldi, FreeSlate's chief executive officer.  "As an independent, private company, we are excited to focus all our talent and energy on a singular purpose: enabling our broad, global customer base to achieve step-change gains in productivity and innovation.  We are fortunate to have a committed, talented team with a track record of success and expertise in high-throughput experimentation."

Following the closing, FreeSlate hired substantially all Symyx employees previously in HPR.  Symyx expects to conclude certain remaining legacy chemical research services contracts by the end of the second quarter of 2010.  As a result of the divestiture and these actions, Symyx is concluding all of its HPR activities other than its ongoing license and royalty entitlements. More information.

Life Tech. Shows Early Sequencing Results
Life Technologies announced early stage results from its single molecule sequencing (SMS) technology at the recent Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida. The new technology uses Qdot nanocrystals as its core sequencing engine.

Qdots are nanometer-sized semiconductor crystals that have made them ideal for groundbreaking cellular imaging research and for the detection of individual protein molecules. Compared to conventional fluorescence detection with organic dye molecules, the Qdot approach generates signals more than 100 times greater, enabling simple single molecule detection. The SMS system uses specially designed sequencing versions of these nanocrystals, attached to proprietary DNA polymerase molecules. For more information.

DREAM3 Papers Published
A collection of papers from the DREAM3 systems biology challenges (Dialogue for Reverse Engineering Assessment and Methods) has been published in PLoS One. Go to and click on the DREAM3 icon.

DREAM organizers are in the process of compiling Challenges for the upcoming DREAM and welcome suggestions. Also, there is a job opening for a research scientist/bioinformatician/software engineer to work on computational methods and tools to support the DREAM project in the Saez-Rodriguez lab at the The European Bioinformatics Institute (EBI), in Hinxton, near Cambridge, UK.  

Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.